Media stories about NovaBay Pharmaceuticals (NYSE:NBY) have trended somewhat negative recently, according to Accern Sentiment. The research group ranks the sentiment of press coverage by monitoring more than 20 million news and blog sources in real-time. Accern ranks coverage of public companies on a scale of -1 to 1, with scores nearest to one being the most favorable. NovaBay Pharmaceuticals earned a media sentiment score of -0.08 on Accern’s scale. Accern also gave media headlines about the company an impact score of 66 out of 100, indicating that recent press coverage is likely to have an effect on the company’s share price in the next several days.
These are some of the news stories that may have effected Accern Sentiment’s scoring:
- NovaBay Pharmaceuticals, Inc. (NYSE:NBY) Downgraded by Zacks Investment Research (americanbankingnews.com)
- NovaBay Pharmaceuticals to Hold 2017 Second … (ih.advfn.com)
- Analysts Anticipate NovaBay Pharmaceuticals, Inc. (NBY) Will Post Quarterly Sales of $4.57 Million (americanbankingnews.com)
- Revance Therapeutics Expands Leadership Team, Appointing Todd Zavodnick Chief Commercial Officer and President, Aesthetics & Therapeutics (businesswire.com)
A number of analysts have recently commented on NBY shares. Zacks Investment Research lowered NovaBay Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Tuesday, April 11th. Maxim Group restated a “hold” rating on shares of NovaBay Pharmaceuticals in a report on Saturday, May 13th. Finally, Roth Capital started coverage on NovaBay Pharmaceuticals in a report on Monday, June 5th. They issued a “buy” rating and a $5.50 price target on the stock. One analyst has rated the stock with a sell rating, one has given a hold rating and four have assigned a buy rating to the company. The company presently has a consensus rating of “Buy” and a consensus price target of $7.00.
NovaBay Pharmaceuticals (NYSE:NBY) traded down 2.4340% during mid-day trading on Tuesday, hitting $4.5856. The company had a trading volume of 11,208 shares. The firm’s market capitalization is $70.20 million. NovaBay Pharmaceuticals has a 12-month low of $2.25 and a 12-month high of $5.29. The company’s 50 day moving average price is $3.83 and its 200-day moving average price is $3.59.
NovaBay Pharmaceuticals Company Profile
NovaBay Pharmaceuticals, Inc, formerly NovaCal Pharmaceuticals, Inc, is a biopharmaceutical company, which develops products for the eye care market. The Company focuses on commercializing prescription Avenova for managing hygiene of the eyelids and lashes in the United States. Avenova is an eye care product formulated with a form of hypochlorous acid called Neutrox.
Receive News & Ratings for NovaBay Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NovaBay Pharmaceuticals Inc. and related companies with our FREE daily email newsletter.